Pharma Mar, S.A.

WHO'M

Digital Profiler. Simply click the AI button

CUSIP

E8075H159

SEDOL

BMW2GT8

CIK

N/A

pharmamar.com

LEI:

FIGI: BBG000F3LRQ5

PHM

Pharma Mar, S.A.

GICS: 35201010 · Sector: Consumer Goods - Pharmacy Products and Biotechnology · Sub-Sector: -

PROFILER

NAME

Pharma Mar, S.A.

ISIN

ES0169501022

TICKER

PHM

MIC

XMAD

REUTERS

PHM.MC

BLOOMBERG

PHM SM

BUILD THEMEFOLIO SHARE IDEAS DISCUSS

LEVERAGE INVEST

Financial Intelligence

360°^iHub Crowd^iFeed ATH Tracker Index Tracker ETF TF Spicy² X-Billboard

FOR INVESTORS

FOR TRADERS

Securities Trading Warrants

TradingView ActivTrader MT4 MT5

In this section you will find transaction histories for short sales.

NALIZER

Transaction history

The overview shows all positions and their last reported status. Please note that when reducing positions, falling below the 0.50% limit means that the mandatory reporting obligations no longer have to be applied. As a rule, it can be assumed that the positions have been completely reduced following a longer period of inactivity. Positions < 0.50% are therefore only of limited significance.

Date	Position Holder	Position	#
01.10.2024	Citadel Advisors LLC	0,49%	28
24.07.2024	Arrowstreet Capital, Limited Partnership	0,49%	12
18.03.2022	AHL PARTNERS LLP	0,48%	14
28.02.2022	D. E. Shaw & Co., L.P.	0,47%	2
28.07.2021	Consonance Capital	0,48%	6
22.01.2021	WorldQuant, LLC	0,47%	14
11.12.2020	Great Point Partners, LLC	0,42%	4
03.12.2020	Point72 Asset Management, L.P.	0,42%	2
08.05.2020	PDT Partners, LLC	0,49%	6
20.03.2020	Winton Capital Management	0,45%	2
27.12.2019	Marshall Wace LLP	0,47%	20
27.11.2017	Wellington Managment Company, LLP	0,49%	10

SHORT SELLING RADAR (“SSR”)

SSR - First TIMER

SSR - DASHBOARD

HEDGE FUND ACTIVITY TRACKER

SSR Weight WATCHER

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

Legend

The information provided in this area is compiled with care and prepared and processed in complex technical process steps. Quality assurance is an integral part of the methods and procedures used. A plausibility check is carried out to the extent that the source data allows. Before further use, especially in the course of any investment decisions, we recommend consulting at least one second independent source for validation.

SMART * AD

P R O D U C T S U G G E S T I O N S

First Name *

Last Name

Email *

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

Please log in to your user account. This will allow us to contact you in case of any queries.

I would like to remain anonymous.

Pharma Mar, S.A.

Newsletter